Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB). ABSTRACT Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB). The newly approved regimen combining BDQ with pretomanid and linezolid is the first 6-month oral regimen proven to be effective against MDR/XDR-TB. However, the emergence of BDQ resistance, primarily due to inactivating mutations in the Rv0678 gene encoding a repressor of the MmpS5-MmpL5 transporter, threatens to undermine the efficacy of new BDQ-containing regimens. Since the shift in MIC due to these mutations is relatively small (2–8×), safer, and more potent, diarylquinoline analogues may be more effective than BDQ. TBAJ-876, which is in phase 1 trials, has more potent in vitro activity and a superior pre-clinical safety profile than BDQ. Using a murine model of TB, we evaluated the dose-dependent activity of TBAJ-876 compared to BDQ against the wild-type H37Rv strain and an isogenic Rv0678 loss-of-function mutant. Although the mutation affected the MIC of both drugs, the MIC of TBAJ-876 against the mutant was 10-fold lower than that of BDQ. TBAJ-876 at doses ≥6.25 mg/kg had greater efficacy against both strains compared to BDQ at 25 mg/kg, when administered alone or in combination with pretomanid and linezolid. Likewise, no selective amplification of BDQ-resistant bacteria was observed at TBAJ-876 doses ≥6.25 mg/kg. These results indicate that replacing BDQ with TBAJ-876 may shorten the duration of TB treatment and be more effective in treating and preventing infections caused by Rv0678 mutants.

[1]  N. Fotouhi,et al.  Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis , 2020, Antimicrobial Agents and Chemotherapy.

[2]  J. Sacchettini,et al.  Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis , 2020, Antimicrobial Agents and Chemotherapy.

[3]  F. Balloux,et al.  Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis , 2020, The Lancet. Microbe.

[4]  L. Rigouts,et al.  Characterization of genomic variants associated with resistance to bedaquiline and delamanid in naïve Mycobacterium tuberculosis clinical strains , 2020, bioRxiv.

[5]  A. Crook,et al.  Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis , 2020, The New England journal of medicine.

[6]  W. Denny,et al.  Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline , 2020, Molecules.

[7]  F. Balloux,et al.  Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients , 2020, European Respiratory Journal.

[8]  S. Niemann,et al.  Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon. , 2020, American journal of respiratory and critical care medicine.

[9]  O. Antonova,et al.  Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. , 2020, The Journal of infection.

[10]  W. Denny,et al.  Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology. , 2019, Bioorganic & medicinal chemistry.

[11]  A. Crook,et al.  Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial , 2019, The Lancet. Respiratory medicine.

[12]  S. Keam Pretomanid: First Approval , 2019, Drugs.

[13]  Rick L. Stevens,et al.  The PATRIC Bioinformatics Resource Center: expanding data and analysis capabilities , 2019, Nucleic Acids Res..

[14]  G. Maartens,et al.  A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis , 2019, Expert opinion on drug safety.

[15]  Christopher B. Cooper,et al.  TBAJ-876 Retains Bedaquiline’s Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase , 2019, Antimicrobial Agents and Chemotherapy.

[16]  W. Denny,et al.  3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel , 2019, Bioorganic & medicinal chemistry.

[17]  K. Dheda,et al.  What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment? , 2019, The Indian journal of medical research.

[18]  N. Fotouhi,et al.  Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis , 2019, Antimicrobial Agents and Chemotherapy.

[19]  Nalini Singh,et al.  High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen , 2018, European Respiratory Journal.

[20]  K. Dheda,et al.  Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa , 2018, European Respiratory Journal.

[21]  H. Koornhof,et al.  Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study , 2018, EBioMedicine.

[22]  Christopher B. Cooper,et al.  Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units , 2017, Bioorganic & medicinal chemistry letters.

[23]  Christopher B. Cooper,et al.  6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis , 2017, ACS medicinal chemistry letters.

[24]  O. Antonova,et al.  Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region , 2017, The Journal of antimicrobial chemotherapy.

[25]  P. Converse,et al.  Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis , 2017, Antimicrobial Agents and Chemotherapy.

[26]  Alimuddin Zumla,et al.  Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study , 2017, European Respiratory Journal.

[27]  Bin Wang,et al.  Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis , 2017, Antimicrobial Agents and Chemotherapy.

[28]  Y. Yazdanpanah,et al.  Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis , 2017, European Respiratory Journal.

[29]  L. Rigouts,et al.  Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline , 2016, The Journal of antimicrobial chemotherapy.

[30]  Koen Andries,et al.  Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.

[31]  A. Diacon,et al.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis , 2015, European Respiratory Journal.

[32]  V. Dartois,et al.  Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis , 2015, Antimicrobial Agents and Chemotherapy.

[33]  R. Wintjens,et al.  Mutations in Genes for the F420 Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in Spontaneous In Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis , 2015, Antimicrobial Agents and Chemotherapy.

[34]  E. Caumes,et al.  Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  K. Dooley,et al.  Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug , 2014, The Journal of antimicrobial chemotherapy.

[36]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[37]  B. D. de Jong,et al.  Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline , 2014, PloS one.

[38]  S. Cole,et al.  Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[39]  Jon Cohen,et al.  Infectious disease. Approval of novel TB drug celebrated--with restraint. , 2013, Science.

[40]  K. Andries,et al.  Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[41]  K. Andries,et al.  Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207. , 2011, Future medicinal chemistry.

[42]  K. Andries,et al.  Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis , 2011, PloS one.

[43]  K. Andries,et al.  Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. , 2009, American journal of respiratory and critical care medicine.

[44]  K. Andries,et al.  Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration , 2006, Antimicrobial Agents and Chemotherapy.

[45]  W. Bishai,et al.  Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[46]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[47]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[48]  Yongge Liu,et al.  Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. , 2018, Tuberculosis.